First Head-to-Head Study Shows GreenLight XPS® Laser Therapy Equally Safe And Effective With Faster Recovery As Commonly Used

First Head-to-Head Study Shows GreenLight XPS® Laser Therapy Equally Safe And 
Effective With Faster Recovery As Commonly Used TURP For Treatment Of BPH 
Results from Large Randomized Trial Support Use of Innovative 180 Watt Laser 
Therapy as a Viable Treatment Option for More Than 110 Million Men Worldwide 
with Enlarged Prostate 
MINNETONKA, Minn., May 6, 2013 /CNW/ - Data to be presented tomorrow at the 
American Urological Association (AUA) Annual Meeting demonstrate that 
treatment for Benign Prostatic Hyperplasia (BPH) with GreenLight XPS(®) laser 
therapy with MoXy(®) fiber, instead of transurethral resection of the 
prostate (TURP), results in significantly shorter hospitalization, 
catheterization, and recovery times for patients, while maintaining equivalent 
safety and efficacy. 
"This trial provides important new information that may cause many urologists 
and patients to choose GreenLight™ laser therapy as an alternative to TURP, 
which has long been regarded as the standard surgical treatment for BPH," said 
Professor Alexander Bachmann, M.D., University Hospital Basel, Switzerland, 
and principal investigator in the GOLIATH study. "With faster recovery times, 
less time spent in the hospital and less catheterization time than TURP, 
GreenLight™ is a highly effective therapy for the treatment of BPH." 
The findings from the prospective, multicenter, randomized GOLIATH trial, 
demonstrate the equivalence in safety and effectiveness of the 180W GreenLight 
XPS(®) system for addressing lower urinary tract symptoms associated with 
BPH. Manufactured by American Medical Systems, an Endo Health Solutions Inc. 
(Nasdaq: ENDP) subsidiary, GreenLight XPS(®) is the most widely used BPH 
laser treatment currently on the market. 
"GreenLight™ laser therapy is the leading minimally invasive laser surgical 
treatment for BPH world-wide, and offers patients a proven innovative option 
to TURP," said Camille Farhat, president of AMS. "Left untreated, BPH, and the 
resulting symptoms, can cause permanent damage to the urinary system. We look 
forward to helping more men who undergo surgery for BPH recover faster and 
potentially return to their active lifestyles more quickly." 
During the GreenLight™ procedure, the physician uses a laser to remove 
excess prostate tissue, creating a larger channel for urine flow to pass 
through. The innovative, outpatient procedure is suitable for most patients 
with enlarged prostates, delivers rapid urine flow improvement, and provides 
immediate and lasting relief of lower urinary tract symptoms. GreenLight™( 
)is available in 70 countries and has been used to treat more than 700,000 
patients worldwide. More information is available for physicians at 
www.amsgreenlight.com and for patients at www.greenlightforbph.com. 
GOLIATH Study Trial Design and Results   The GOLIATH study was designed to 
compare TURP and PVP (Photo-Selective Vaporization of the Prostate) with the 
180W GreenLight XPS(®) system using a variety of symptomatic, functional and 
safety outcome measures.  The study evaluated 269 patients from 29 sites in 11 
European countries based on 6-month post procedural results.  All adverse 
events were adjudicated and classified by an independent, blinded clinical 
events committee. 
Key trial findings include: 


    --  Equivalency in safety, as evidenced by the number and rate of
        adverse events, and efficacy, as determined by IPSS
        (International Prostate Symptom Score) and Qmax (peak urinary
        flow rate)
    --  Superiority of GreenLight XPS(®) in recovery times including
        shorter catheterization times, shorter hospital stay, and a
        faster return to a stable health status
    --  Significantly lower rate of short-term re-intervention with
        GreenLight XPS(®)
    --  Numerically fewer bleeding and dysuric events with GreenLight
        XPS(® )than TURP
    --  Comparable prostate tissue volume and PSA (prostate specific
        antigen) reduction

About BPH   More than 110 million men globally suffer from BPH,[1] a condition 
in which an enlarged prostate presses on the urethra, which can obstruct the 
flow of urine and cause problems such as frequent urination, pain or burning 
while urinating, and weak urine flow. If left untreated, BPH can lead to such 
issues as kidney damage,[2] severe urinary tract infections,[3] visible blood 
in the urine,[4] chronic renal failure.[5]  According to the AUA, by 60 years 
of age, BPH prevalence is greater than 50 percent and by age 85 is as high as 
90 percent. BPH is so common it has been said that all men will have an 
enlarged prostate if they live long enough.[6]

About GreenLight XPS®

The GreenLight™ laser system is intended for incision/excision, 
vaporization, ablation, hemostasis and coagulation of soft tissue, including 
photoselective vaporization of the prostate for benign prostatic hyperplasia 
(BPH). The laser system is contraindicated for patients who: are 
contraindicated for surgery, contraindicated where appropriate anesthesia is 
contraindicated by patient history, have calcified tissue, require hemostasis 
in >2mm vessels, have uncontrolled bleeding disorders, have prostate cancer, 
have acute urinary tract infection (UTI) or severe urethral stricture. 
Possible risks and complications that include, but are not limited to, 
irritative symptoms (dysuria, urgency, frequency), retrograde ejaculation, 
urinary incontinence, erectile dysfunction, hematuria - gross, UTI, bladder 
neck contracture/outlet obstruct, urinary retention, perforation - prostate, 
urethral stricture.

About American Medical Systems  American Medical Systems (AMS), headquartered 
in Minnetonka, Minn., is a diversified supplier of medical devices and 
procedures to treat incontinence, erectile dysfunction, benign prostatic 
hyperplasia (BPH), pelvic floor prolapse and other pelvic disorders in men and 
women. AMS continues to develop new therapies to restore bodily functions and 
to enable people to regain control of their lives. AMS is an operating company 
of Endo Health Solutions Inc. (Nasdaq: ENDP), a diversified healthcare company 
that is dedicated to improving care through a combination of branded products, 
generics, devices, technology and services. Learn more at www.endo.com.

Safe Harbor Statement   This press release contains forward-looking statements 
within the meaning of the Private Securities Litigation Reform Act of 1995. 
Statements including words such as "believes," "expects," "anticipates," 
"intends," "estimates," "plan," "will," "may," "look forward," "intend," 
"guidance," "future" or similar expressions are forward-looking statements. 
Because these statements reflect our current views, expectations and beliefs 
concerning future events, these forward-looking statements involve risks and 
uncertainties. Investors should note that many factors, as more fully 
described under the caption "Risk Factors" in Endo Health Solutions' Form 
10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange 
Commission and as otherwise enumerated herein or therein, could affect our 
future financial results and could cause our actual results to differ 
materially from those expressed in forward-looking statements contained in the 
Endo Health Solutions Annual Report on Form 10-K. The forward-looking 
statements in this press release are qualified by these risk factors. These 
are factors that, individually or in the aggregate, could cause our actual 
results to differ materially from expected and historical results. We assume 
no obligation to publicly update any forward-looking statements, whether as a 
result of new information, future developments or otherwise.

[1] (AMS ppt:  Benign Prostatic Hyperplasia, Understanding Market Size and 
Patient Flow:  An Analysis of Census Data and Available Literature 2010)

[2] Carter HB. Prostate Disorders: The Johns Hopkins White Papers. Baltimore, 
MD: Johns Hopkins Medicine; 2010:1-24.

[3] Urinary tract infections. US National Library of Medicine, National 
Institute of Health. 
http://www.nlm.nih.gov/medlineplus/ency/article/000521.htm. Accessed Oct. 27, 
2010.

[4] Enlarged prostate. US National Library of Medicine, National Institute of 
Health. http://www.nlm.nih.gov/medlineplus/ency/article/000381.htm. Accessed 
Sept. 27, 2010.

[5] Aging changes in the male reproductive system: MedlinePlus Medical 
Encyclopedia. National Institutes of Health. 
http://www.nlm.nih.gov/medlineplus/ency/article/004017.htm. Accessed Nov 22, 
2011.

[6] Enlarged prostate. US National Library of Medicine, National Institute of 
Health. http://www.nlm.nih.gov/medlineplus/ency/article/000381.htm. Accessed 
Sept. 27, 2010.


Investors/Media: Blaine Davis, (484) 216-7158, or Media:  Brian O'Donnell, 
(484) 216-6726, or Investors: Jonathan Neely, (484) 216-6645 
http://www.endo.com 
SOURCE: American Medical Systems 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/May2013/06/c4084.html 
CO: American Medical Systems
ST: Minnesota
NI: HEA MTC NUTRITION HEALTH SHOW  
-0- May/06/2013 20:55 GMT